5-hydroxypyrazinoic acid
2-pyrazinecarboxylic acid, 5-hydroxy-
Identification
| Name | 5-hydroxypyrazinoic acid |
| IUPAC | 6-oxo-1H-pyrazine-3-carboxylic acid |
| CAS Number | 34604-60-9 |
| FDA UNII | M2V0DP3ENP |
| Molecular Formula | C5 H4 N2 O3 |
| Molecular Weight | 140.09848000 |
| MDL Number | MFCD00190599 |
| Nikkaji Number | J47.668D |
| Beilstein | 775641 |
Regulatory
Physical Properties
| Assay | 95.00 to 100.00 |
| Food Chemicals Codex Listed | No |
| Boiling Point | 608.50 °C. @ 760.00 mm Hg (est) |
| Flash Point | 611.00 °F. TCC ( 321.80 °C. ) (est) |
| logP (o/w) | -1.820 (est) |
| Soluble in | water, 6.99e+004 mg/L @ 25 °C (est) |
No sensory data available
Safety Information
| Preferred SDS | View |
| Oral/Parenteral Toxicity | Not determined |
| Dermal Toxicity | Not determined |
| Inhalation Toxicity | Not determined |
GHS Classification
['GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)', 'GHS Label elements, including precautionary statements']
Safety in Use
| Category | information only not used for fragrances or flavors |
| Recommendation for 5-hydroxypyrazinoic acid usage levels up to | not for fragrance use. |
| Recommendation for 5-hydroxypyrazinoic acid flavor usage levels up to | not for flavor use. |
BOC Sciences
Best of Chemicals Supplier
Quality supplier of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecul...
Potential Uses
Natural Occurrence
Synonyms
5-
hydroxy-2-pyrazinecarboxylic acid
5-
hydroxypyrazine-2-carboxylic acid
6-oxo-1H-
pyrazine-3-carboxylic acid
2-
pyrazinecarboxylic acid, 5-hydroxy-
PubMed:
A novel mechanism underlies the hepatotoxicity of pyrazinamide.
PubMed:
Investigation of the effects of concomitant caffeine administration on the metabolic disposition of pyrazinamide in rats.
PubMed:
Quantification of pyrazinamide and its metabolites in plasma by ionic-pair high-performance liquid chromatography. Implications for the separation mechanism.
PubMed:
Determination of pyrazinamide and its main metabolites in rat urine by high-performance liquid chromatography.
PubMed:
Ethanol as a xanthine dehydrogenase inhibitor.
PubMed:
Xylitol-induced increase in the concentration of oxypurines and its mechanism.
PubMed:
In vitro oxidation of pyrazinamide and allopurinol by rat liver aldehyde oxidase.
PubMed:
A case of xanthinuria: a study on the metabolism of pyrazinamide and allopurinol.
PubMed:
Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.
PubMed:
Metabolism of pyrazinamide and allopurinol in hereditary xanthine oxidase deficiency.
PubMed:
[Microdetermination of pyrazinamide and its metabolites (pyrazinoic acid, 5-hydroxypyrazinoic acid, 5-hydroxypyrazinamide and pyrazinuric acid) in plasma and urine with liquid chromatography].
PubMed:
In vitro conversion of pyrazinamide into 5-hydroxypyrazinamide and that of pyrazinoic acid into 5-hydroxypyrazinoic acid by xanthine oxidase from human liver.
PubMed:
Metabolic disposition of pyrazinamide in the rat: identification of a novel in vivo metabolite common to both rat and human.
PubMed:
Study of the metabolism of pyrazinamide using a high-performance liquid chromatographic analysis of urine samples.
PubMed:
Study of urinary pyrazinamide metabolites and their action on the renal excretion of xanthine and hypoxanthine in a xanthinuric patient.
PubMed:
Mass fragmentographic determination of pyrazinamide and its metabolites in serum and urine.
PubMed:
Observations on the reduction of the renal elimination of urate in man caused by the administration of pyrazinamide.